'Cytokine storms' are a deadly problem in COVID-19. Researchers are testing promising solutions.


Some of the worst cases of COVID-19 involve patients who appear to get better then suddenly deteriorate, their lungs and other organs failing under an overwhelming immune response called a "cytokine storm." Cytokines are proteins sent out by a body's adaptive immune system — B and T cells — to recruit other immune cells to fight an infection. When the immune system doesn't shut off the cytokines, a storm of cells overwhelms organs, exhausting a body's immune response, causing dangerous inflammation, and attacking healthy tissues.
In COVID-19, scavenger cells called macrophages apparently attack and inflame the lungs, allowing liquid to fill air sacs and causing acute respiratory distress syndrome. An otherwise healthy woman in her 20s had a double lung transplant because COVID-19 irreparably destroyed her lungs, a Chicago hospital announced Thursday.
"It has become increasingly clear in the past few months that, at least in a subset of people who have the virus, calming the storm is the key to survival," The New York Times reports. Researchers are starting trials on several drugs to prevent or pacify cytokine storms, and others have reported some success with a dialysis-like device called CytoSorb that filters out cytokines from a patient's blood and returns it to the body.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In China and Italy, doctors had some success with a drug called tocilizumab, marketed as Actemra by Roche, which blocks the cytokine interleukin-6 (IL-6). Another drug, Kineret, blocks a different cytokine, IL-1. A recent study published in the journal Science Immunology reported promising preliminary results from an AstraZeneca cancer drug called Calquence, or acalabrutinib, which aims to stop the cytokines at their root. Using a drug like tocilizumab is "like cutting the branches off a tree," Dr. Louis Staudt, a National Cancer Institute scientist and a lead investigator on the study, tells the Times. "Acalabrutinib is going for the trunk of the tree." AstraZeneca has plans to test the drug in larger trials.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
5 heavy-handed cartoons about ICE and deportation
Cartoons Artists take on international students, the Supreme Court, and more
By The Week US
-
Exploring the three great gardens of Japan
The Week Recommends Beautiful gardens are 'the stuff of Japanese landscape legends'
By The Week UK
-
Is Prince Harry owed protection?
Talking Point The Duke of Sussex claims he has been singled out for 'unjustified and inferior treatment' over decision to withdraw round-the-clock security
By The Week UK
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
By Peter Weber, The Week US
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
By Justin Klawans, The Week US
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
By Peter Weber, The Week US
-
Trump's China tariffs start after Canada, Mexico pauses
Speed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
By Peter Weber, The Week US
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
By Peter Weber, The Week US
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine
By Peter Weber, The Week US
-
Biden expected to block Japanese bid for US Steel
Speed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
By Peter Weber, The Week US
-
Judges block $25B Kroger-Albertsons merger
Speed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
By Peter Weber, The Week US